Roivant reports ~80% durability and ~50% ATD-free remission in Graves' disease data

Roivant Sciences Ltd.

Of 21 patients in 6-month off-treatment follow-up, ~80% (17/21) maintained normal thyroid function.
~50% of responders (8/17) achieved anti-thyroid drug-free remission after 6 months off batoclimab.
Two registrational trials for IMVT-1402 in Graves' disease are enrolling; topline data expected 2027.
Safety consistent with prior batoclimab studies; first potential disease-modifying therapy for uncontrolled GD.
Roivant and Immunovant to host investor call Sept 3, 2025 at 4:30 p.m. EDT to discuss data.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.